- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| CORNERSTONE THERAPEUTICS Aktie jetzt für 0€ handeln |
0 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| GILEAD SCIENCES | 125,60 | -0,11 % | AWSX der Telegram-Trader.de: Gilead:Trodelvy bekommt in Europa deutlich mehr Gewicht-Wo liegen die Kursziele? | ||
| ZOETIS | 67,04 | +0,45 % | Zoetis: Analysten warnen - doch das könnte alles ändern | ||
| INCYTE | 107,20 | -0,14 % | H.C. Wainwright bestätigt Kursziel für Incyte Aktie bei 150 US-Dollar | ||
| AMARIN | 12,000 | 0,00 % | Amarin Corporation plc: New REDUCE-IT Legacy Analysis Presented at European Society of Cardiology (ESC) Congress 2026 Suggests Persistent Cardiovascular Benefit Following Icosapent Ethyl Treatment Cessation in Adherent Patients | ||
| FILANA THERAPEUTICS | 0,804 | +1,00 % | Filana Therapeutics, Inc.: Filana Therapeutics Reports Q2 2026 Financial Results and Provides Business Update | AUSTIN, Texas, July 29, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, "Filana Therapeutics", the "Company"), a biotechnology company currently focused on developing therapies for... ► Artikel lesen | |
| LIGAND PHARMACEUTICALS | 242,00 | 0,00 % | Ligand Pharmaceuticals: Royalty-Modell gewinnt an Dynamik | ||
| ACHIEVE LIFE SCIENCES | 7,100 | +1,43 % | Achieve Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Updates | Closed a private placement of up to $354 million, with $180 million upfront and up to $174 million from warrants exercisable prior to and up to 20 trading days following FDA approval Strengthened... ► Artikel lesen | |
| MADRIGAL PHARMACEUTICALS | 463,70 | +0,56 % | Here's Exactly What It Will Take for Madrigal Pharmaceuticals Stock to Take Off | ||
| ANI PHARMACEUTICALS | 62,50 | 0,00 % | ANI Pharmaceuticals, Inc.: ANI Pharmaceuticals Appoints Henry Gosebruch to Board of Directors | - Appointment strengthens board as ANI accelerates transformation into a leading Rare Disease Company - PRINCETON, N.J., Aug. 24, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company)... ► Artikel lesen | |
| TALPHERA | 1,040 | 0,00 % | Talphera, Inc.: Talphera Announces First Quarter 2026 Financial Results and Provides Corporate Update | NEPHRO CRRT clinical study expected to be completed this year
Cash and investments of $21.1 million at March 31, 2026
Conference call and webcast to be held on Wednesday... ► Artikel lesen | |
| RIGEL PHARMACEUTICALS | 39,400 | -1,84 % | Rigel Pharmaceuticals, Inc.: Rigel Reports Second Quarter 2026 Financial Results | Second quarter 2026 total revenues of $78.7 million, including net product sales of $67.0 million and contract revenues from collaborations of $11.7 million, and... ► Artikel lesen | |
| SAVARA | 4,533 | -3,68 % | Savara Inc.: Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (APAP) at the European Respiratory Society (ERS) Congress 2026 | -- Company to Host Industry Evening Mini-Symposium on aPAP with Renowned Key Opinion Leaders --Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases... ► Artikel lesen | |
| BIODEXA PHARMACEUTICALS | 0,868 | 0,00 % | Biodexa Pharmaceuticals PLC: Biodexa announces major milestone for its Serenta registrational Phase 3 trial in FAP | August 19, 2026 Biodexa announces major milestone for its Serenta registrational Phase 3 trial in FAP 87 subjects, over 50% of target, recruited Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) ("Biodexa"... ► Artikel lesen | |
| ARTIVION | 22,800 | -2,56 % | Artivion, Inc.: Artivion Reports Second Quarter 2026 Financial Results | Second Quarter & Recent Business Highlights:
Achieved revenue of $125.8 million in the second quarter of 2026 versus $113.0 million in the second quarter of 2025... ► Artikel lesen | |
| HERON THERAPEUTICS | 0,281 | +0,57 % | Heron Therapeutics, Inc.: U.S. District Court Issues Decision Regarding CINVANTI Patents | CARY, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the U.S. District Court... ► Artikel lesen |
CORNERSTONE THERAPEUTICS INC gehört der Branche Pharma an.
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CORNERSTONE THERAPEUTICS INC finden Sie auf Wallstreet Online.